Shijiazhuang Yiling Pharmaceutical: The performance of respiratory products is affected by the high base in previous years and the high inventory in hospitals, related sales will gradually return to normal | Directly targeting the earnings conference
①Due to factors such as the high base number of the previous year and the high social inventory, which led to a decrease in market demand, respiratory products were affected, resulting in a decline in performance. In the future, the company's sales of respiratory products will gradually return to normal. ② The company expects that both the cardiovascular and cerebrovascular block order products, as well as the secondary products like Bazibu Shen, anxiety relief, etc., have good market potential. The future performance of respiratory system new products is also promising, and the company will continue to build a core product cluster.
Huadong Medicine targets 'Suyan Zhen' infringement! What is the purpose of the two 'Girl's Needles' fighting each other across space?
①Huadong Medicine's "Iyan Shi" claims that Caicai Medical's "Suyan Zhen" infringes on its invention patent rights, and has now filed a civil lawsuit; ② Caicai Medical's parent company Guyu Chun denied this statement, and as of now, the market launch of "Suyan Zhen" is less than two months old; ③ Industry insiders believe that it is difficult to determine whether Guyu Chun has engaged in infringement at this time.
Unveil! With huge trading volume, which A-shares are institutions chasing after?
The heat of A shares is still continuing!
Express News | Contract research organizations surged violently in the final trading session of Hong Kong stocks, with Tigermed soaring nearly 28%, Pharmaron rising over 22%, Joinn Laboratories up more than 17%, Wuxi Apptec up over 16%, and Wuxi Bio up over 14%.
Hong Kong stocks have been soaring for days on heavy volume, haven't jumped on board yet? These directions are still worth paying attention to.
In recent days, the heavy-duty policy bullish continues to catalyze, with large funds actively buying assets in China, and the market's bullish sentiment towards China has been fully ignited. Beneficiary sectors have already risen in advance. Lowering mortgage rates is bullish for consumer spending, with sectors like alcohol, gold, and jewelry taking the lead, while opportunities for biomedical and real estate stocks are worth looking forward to.
Long-serving senior executive of lepu medical technology resigns, can the second generation successor stop the decline in performance? | Express announcement
①Tonight, lepu medical technology announced the resignation of General Manager Zhang Zhibin and Deputy General Manager Zheng Guorui, with Chairman's daughter Pu Fei taking over as General Manager, who has a background of "sea turtle elite"; ②Starting from 2023, lepu medical technology's performance has declined for several consecutive quarters, with market cap dropping by a quarter compared to the peak period.